Intravenous immunoglobulin and dendritic cells.
Intravenous immunoglobulin (IVIg) has increasingly been used for the treatment of autoimmune and systemic inflammatory diseases, and in supportive therapy of immunodeficient patients. Available clinical and experimental evidence suggests, however, that a wide spectrum of immune-mediated conditions could benefit from IVIg, including acute and chronic/relapsing diseases and autoimmune diseases mediated by pathogenic autoantibodies or by autoaggressive T-cells. Dendritic cells (DCs) are professional antigen-presenting cells and because of their capacity to stimulate naïve T-cells, they play a central role in the initiation of primary immune responses. Several immunomodulatory agents have been shown to inhibit DC activation. Recently, we examined the effects of IVIg on differentiation, maturation, and functions of DCs. We demonstrate that DCs are one of the targets for the immunomodulatory effects of IVIg.
Misra
Namita
N
Inserm, U681, Paris, France.
Bayry
Jagadeesh
J
Bayary
Jagadeesh
J
Dasgupta
Sooryasarathi
S
Ephrem
Amal
A
Huyen
Jean-Paul Duong Van
JP
Delignat
Sandrine
S
Hassan
Gazzala
G
Caligiuri
Giuseppina
G
Nicoletti
Antonino
A
Lacroix-Desmazes
Sebastien
S
Kazatchkine
Michel D
MD
Kaveri
Srini V
SV
D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects / Q000276:immunology; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects* / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000494:pharmacology*
D016756:Immunoglobulins, Intravenous